DelveInsight估计，到2032年，帕金森病精神病市场可能会稳步增长-动脉网

Parkinson's Disease Psychosis Market is Likely to Increase at a Steady Growth Rate by 2032, Estimates DelveInsight

CISION 等信源发布 2023-10-03 05:01



可切换为仅中文







The dynamics of the Parkinson's disease psychosis market are anticipated to change in the coming years owing to the improvement in diagnosis methodologies, rising awareness of the disease, incremental healthcare spending worldwide, and the expected launch of emerging therapies

由于诊断方法的改进，对该疾病的认识不断提高，全球医疗保健支出的增加以及预期的新兴疗法的推出，帕金森病-精神病市场的动态预计将在未来几年发生变化

LAS VEGAS, Oct. 2, 2023 /PRNewswire/ -- DelveInsight's Parkinson's Disease Psychosis Market Insights report includes a comprehensive understanding of current treatment practices, Parkinson's disease psychosis emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan]..

拉斯维加斯，2023年10月2日/PRNewswire/-DelveInsight的帕金森病精神病市场洞察力报告包括全面了解当前的治疗实践，帕金森病精神病新兴药物，个体治疗的市场份额以及2019年至2032年的当前和预测市场规模，分为7MM[美国，EU-4（意大利，西班牙，法国和德国），英国和日本]）。。

Key Takeaways from the Parkinson's Disease Psychosis Market Report

帕金森病精神病市场报告的主要收获

According to DelveInsight analysis, the Parkinson's disease psychosis market is anticipated to increase at a significant CAGR during the forecast period due to the expected launch of emerging therapies.

根据DelveInsight分析，由于预计将推出新兴疗法，预计帕金森病精神病市场将在预测期间以显着的CAGR增长。

As per DelveInsight's estimates, the total 7MM prevalent cases of Parkinson's disease psychosis in 2022 were ~460K out of which the highest prevalent cases were in the US.

根据DelveInsight的估计，2022年共有7MM的帕金森病精神病流行病例约为460K，其中流行病例最多的是美国。

Globally, leading Parkinson's disease psychosis companies such as Vanda Pharmaceuticals, Kyowa Kirin, Inc., Sage Therapeutics, Athira Pharma, Aptinyx, CogState Ltd., AgeneBio, 1ST Biotherapeutics, Inc., ACADIA Pharmaceuticals Inc., BrainX Corporation, CuraSen Therapeutics, Inc., and others are developing novel Parkinson's disease psychosis drugs that can be available in the Parkinson's disease psychosis market in the coming years..

在全球范围内，领先的帕金森氏病精神病公司，例如Vanda Pharmaceuticals，Kyowa Kirin，Inc.，Sage Therapeutics，Athira Pharma，Aptinyx，CogState Ltd.，AgeneBio，1ST Biotherapeutics，Inc.，ACADIA Pharmaceuticals Inc.，BrainX Corporation，CuraSen Therapeutics，Inc。，其他人正在开发新的帕金森病精神病药物，这些药物可在未来几年内在帕金森病精神病市场上销售。。

Some key therapies for Parkinson's disease psychosis treatment include Iloperidone, Istradefylline, SAGE-718, ATH-1017, NYX-458, and others.

帕金森病精神病治疗的一些关键疗法包括伊洛哌啶酮，Istradefylline，SAGE-718，ATH-1017，NYX-458等。

Discover which therapies are expected to grab the major Parkinson's disease psychosis market share @ Parkinson's Disease Psychosis Market Report

发现哪些疗法有望抓住主要的帕金森病-精神病市场份额@帕金森病-精神病市场报告

Parkinson's Disease Psychosis Overview

帕金森病精神病概述

Parkinson's disease psychosis (PDP) is a complex and often distressing complication that can affect individuals living with Parkinson's disease. This condition is characterized by a range of neuropsychiatric symptoms, including hallucinations, delusions, and paranoia. The exact causes of PDP are not fully understood, but they are believed to be multifactorial.

帕金森病精神病（PDP）是一种复杂且经常令人痛苦的并发症，可影响帕金森病患者。这种情况的特征是一系列神经精神症状，包括幻觉，妄想和偏执狂。PDP的确切原因尚未完全了解，但它们被认为是多因素的。

Symptoms of PDP can vary from person to person but often include visual hallucinations, where individuals see things that are not there, and delusions, which are false beliefs that can be paranoid or grandiose in nature. These symptoms can be particularly distressing for both the affected individuals and their caregivers, leading to a decreased quality of life..

PDP的症状因人而异，但通常包括视觉幻觉，个人看到不存在的东西，以及妄想，这是错误的信念，可能是偏执或宏大的性质。这些症状对于受影响的个人及其护理人员而言尤其令人痛苦，从而导致生活质量下降。。

Diagnosing PDP can be challenging because these symptoms can overlap with other conditions or medication side effects. Healthcare providers typically rely on a thorough clinical evaluation, including a detailed medical history and neurological examination, to make a diagnosis. Imaging studies, such as MRI or CT scans, may be used to rule out other causes of psychosis.

诊断PDP可能具有挑战性，因为这些症状可能与其他病症或药物副作用重叠。医疗保健提供者通常依靠全面的临床评估（包括详细的病史和神经系统检查）进行诊断。成像研究，如MRI或CT扫描，可用于排除精神病的其他原因。

In some cases, a trial of adjusting Parkinson's medications is conducted to see if the psychosis improves, which can further support the diagnosis..

在某些情况下，进行调整帕金森药物的试验，看看精神病是否有所改善，这可以进一步支持诊断。。

Parkinson's Disease Psychosis Epidemiology Segmentation

帕金森病精神病流行病学细分

The Parkinson's disease psychosis epidemiology section provides insights into the historical and current Parkinson's disease psychosis patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. .

帕金森病-精神病流行病学部分提供有关帕金森病-精神病患者历史和当前的见解，并预测七个主要国家的趋势。它通过探索众多研究和主要意见领袖的观点，有助于认识当前和预测趋势的原因。 .

The Parkinson's disease psychosis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

帕金森病精神病市场报告提供了2019-2032年研究期间的流行病学分析，分为7MM分为：

Parkinson's Disease Psychosis Prevalent Cases

帕金森病精神病流行病例

Prevalent Cases of Parkinson's Disease Psychosis Based on Gender

基于性别的帕金森病精神病流行病例

Prevalence of Parkinson's Disease Psychosis Based on Symptoms

基于症状的帕金森病精神病患病率

Parkinson's Disease Psychosis Age-Specific Prevalent Cases

帕金森病精神病年龄特异性流行病例

Parkinson's Disease Psychosis Treatment Market

帕金森病精神病治疗市场

In the treatment of Parkinson's disease psychosis, a comprehensive and patient-centered approach is essential. Beyond medication adjustments and antipsychotic drugs, healthcare providers often delve into addressing potential underlying causes. This may involve investigating medical conditions, such as infections or metabolic imbalances, that can exacerbate psychotic symptoms and ensuring their proper management.

在帕金森病精神病的治疗中，全面和以患者为中心的方法至关重要。除了药物调整和抗精神病药物之外，医疗保健提供者经常深入研究解决潜在的根本原因。这可能涉及调查可能加剧精神病症状并确保其适当管理的医疗状况，例如感染或代谢失衡。

Moreover, non-pharmacological strategies are gaining prominence in the treatment of Parkinson's disease psychosis. Psychosocial interventions like cognitive-behavioral therapy (CBT) can help patients and their caregivers better cope with the emotional challenges posed by psychosis. CBT can equip individuals with strategies to understand, manage, and reduce distress associated with hallucinations and delusions..

此外，非药物策略在治疗帕金森病精神病方面越来越突出。像认知行为疗法（CBT）这样的心理社会干预可以帮助患者及其护理人员更好地应对精神病带来的情绪挑战。CBT可以为个人提供理解，管理和减少与幻觉和妄想相关的痛苦的策略。。

Support groups are another valuable resource. They provide a platform for patients and their families to share experiences and gain insights into dealing with Parkinson's disease psychosis, fostering a sense of community and emotional support. In addition, educating caregivers about the condition and its management is crucial.

支持小组是另一个宝贵的资源。他们为患者及其家属提供了一个平台，分享经验，深入了解帕金森病精神病的治疗方法，培养社区和情感支持感。此外，教育照顾者关于病情及其管理至关重要。

This not only helps in creating a more supportive environment but also ensures that potential side effects of medications are closely monitored, helping to strike the right balance between controlling psychosis and preserving motor function. Continual evaluation and adjustments to the treatment plan are vital, as the nature and severity of Parkinson's disease psychosis can fluctuate over time.

这不仅有助于创造一个更有利的环境，而且还确保密切监测药物的潜在副作用，有助于在控制精神病和保持运动功能之间取得正确的平衡。对治疗计划的持续评估和调整至关重要，因为帕金森病精神病的性质和严重程度可能随时间波动。

By combining medical, psychological, and social interventions, healthcare providers aim to enhance the overall well-being and quality of life for individuals living with this challenging aspect of Parkinson's disease..

通过结合医疗，心理和社会干预措施，医疗保健提供者的目标是提高帕金森病这一具有挑战性的方面的个人的整体健康和生活质量。。

To know more about Parkinson's disease psychosis treatment, visit @ Parkinson's Disease Psychosis Treatment Drugs

要了解更多关于帕金森病精神病治疗的信息，请访问@Parkinson's disease psychosis treatment Drugs

Key Parkinson's Disease Psychosis Therapies and Companies

关键帕金森病精神病治疗和公司

Iloperidone: Vanda Pharmaceuticals

Iloperidone：万达制药

Istradefylline: Kyowa Kirin, Inc.

Istradefylline:Kyowa Kirin，Inc。

SAGE-718: Sage Therapeutics

SAGE-718:SAGE Therapeutics

ATH-1017: Athira Pharma

ATH-1017:Athira Pharma

NYX-458: Aptinyx

NYX-458:Aptinyx

Learn more about the FDA-approved drugs for Parkinson's disease psychosis @ Drugs for Parkinson's Disease Psychosis Treatment

了解更多关于FDA批准的帕金森病精神病药物@帕金森病精神病治疗药物

Parkinson's Disease Psychosis Market Dynamics

帕金森病精神病市场动态

The Parkinson's disease psychosis market dynamics have witnessed significant shifts in recent years. As the understanding of PDP's debilitating effects on patients has grown, so too has the urgency to develop effective treatments. This has led to intensified research and development efforts, resulting in a robust pipeline of potential therapies.

帕金森病精神病市场动态近年来发生了重大变化。随着对PDP对患者的衰弱作用的理解的增加，开发有效治疗的紧迫性也在增加。这导致了加强的研究和开发工作，形成了强大的潜在疗法渠道。

Additionally, the aging global population, a key demographic for PDP, has increased the prevalence of the condition, thereby expanding the potential Parkinson's disease psychosis market size. .

此外，全球人口老龄化是PDP的一个关键人口，增加了该病的患病率，从而扩大了潜在的帕金森病-精神病市场规模。 .

Moreover, the pharmaceutical industry's involvement in PDP treatment development is intensifying, with numerous companies investing in novel therapeutic approaches. These include drugs targeting the neurochemical imbalances responsible for PDP symptoms, as well as non-pharmacological interventions like advanced neurostimulation techniques and behavioral therapies.

此外，制药业对PDP治疗发展的参与正在加剧，许多公司投资于新的治疗方法。这些药物包括针对负责PDP症状的神经化学失衡的药物，以及非药物干预措施，如先进的神经刺激技术和行为疗法。

This expanding range of treatment options is expected to diversify the market and provide more choices for patients and physicians alike..

预计这种扩大的治疗方案范围将使市场多样化，并为患者和医生提供更多选择。。

Nonetheless, the path to bringing new treatments to the Parkinson's disease psychosis market remains fraught with challenges. Rigorous clinical trials and regulatory approvals are necessary but time-consuming processes. Additionally, the variability in PDP symptoms and patient responses to treatment present complexities that demand tailored approaches..

尽管如此，为帕金森病精神病市场带来新疗法的途径仍然充满了挑战。严格的临床试验和监管审批是必要的，但耗时的过程。此外，PDP症状的变化和患者对治疗的反应呈现出需要量身定制方法的复杂性。。

As the PDP market dynamics continue to evolve, stakeholders are not only navigating these challenges but also working towards a future where PDP management is more accessible, effective, and compassionate. The ultimate goal is to improve the quality of life for the millions of individuals affected by PDP, offering them and their families hope for a better tomorrow.

随着PDP市场动态的不断发展，利益相关者不仅在应对这些挑战，而且还在努力实现PDP管理更容易获得，有效和富有同情心的未来。最终目标是提高数百万受PDP影响的个人的生活质量，为他们和他们的家人提供更好的明天的希望。

This evolution in the PDP market underscores the importance of continued research, innovation, and collaboration within the medical and pharmaceutical communities to address this pressing medical need..

PDP市场的这种发展强调了医疗和制药社区内持续研究，创新和合作以解决这一紧迫医疗需求的重要性。。

Report Metrics

报告指标

Details

细节

Study Period

学习期

2019–2032

Coverage

新闻报道

7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]

7MM[美国、欧盟4国（德国、法国、意大利和西班牙）、英国和日本]

Key Parkinson's Disease Psychosis Companies

关键帕金森病精神病公司

Vanda Pharmaceuticals, Kyowa Kirin, Inc., Sage Therapeutics, Athira Pharma, Aptinyx, CogState Ltd., AgeneBio, 1ST Biotherapeutics, Inc., ACADIA Pharmaceuticals Inc., BrainX Corporation, CuraSen Therapeutics, Inc., and others

Vanda Pharmaceuticals，Kyowa Kirin，Inc.，Sage Therapeutics，Athira Pharma，Aptinyx，CogState Ltd.，AgeneBio，1ST Biotherapeutics，Inc.，ACADIA Pharmaceuticals Inc.，BrainX Corporation，CuraSen Therapeutics，Inc.等

Key Parkinson's Disease Psychosis Therapies

关键帕金森病精神病治疗

Iloperidone, Istradefylline, SAGE-718, ATH-1017, NYX-458, and others

Iloperidone，Istradefylline，SAGE-718，ATH-1017，NYX-458等

Scope of the Parkinson's Disease Psychosis Market Report

帕金森病精神病市场报告的范围

Therapeutic Assessment: Parkinson's Disease Psychosis current marketed and emerging therapies

治疗评估：帕金森病精神病目前市场和新兴疗法

Parkinson's Disease Psychosis Market Dynamics: Conjoint Analysis of Emerging Parkinson's Disease Psychosis Drugs

帕金森病精神病市场动态：新兴帕金森病精神病药物的联合分析

Competitive Intelligence Analysis: SWOT analysis and Market entry strategies

竞争智力分析：SWOT分析和市场准入策略